AG˹ٷ

STOCK TITAN

[Form 4] UNITEDHEALTH GROUP INCORPORATED (Delaware) Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

UnitedHealth Group Inc. (UNH) � Form 4 filing dated 26-Jun-2025

Director John H. Noseworthy reported the automatic acquisition of 42 shares of common stock on 24-Jun-2025. The shares represent dividend equivalents on previously vested deferred stock units and were credited at a transaction price of $0.00. Following this routine credit, Noseworthy’s direct ownership rises to 6,105 shares. No derivative transactions or dispositions were reported, and the filing indicates the transaction was not executed under a Rule 10b5-1 trading plan. The small share count and zero-cost basis signal an administrative, non-market purchase with limited impact on public float or insider sentiment.

UnitedHealth Group Inc. (UNH) � Comunicazione Form 4 del 26 giugno 2025

Il direttore John H. Noseworthy ha riportato l'acquisizione automatica di 42 azioni ordinarie il 24 giugno 2025. Le azioni rappresentano equivalenti di dividendi su unità azionarie differite precedentemente maturate e sono state accreditate a un prezzo di transazione di $0,00. A seguito di questo accredito ordinario, la proprietà diretta di Noseworthy sale a 6.105 azioni. Non sono state segnalate operazioni o cessioni di strumenti derivati e la comunicazione indica che la transazione non è stata eseguita nell'ambito di un piano di trading Rule 10b5-1. Il numero limitato di azioni e il costo nullo indicano un acquisto di natura amministrativa, senza impatto significativo sul flottante pubblico o sul sentiment degli insider.

UnitedHealth Group Inc. (UNH) � Presentación del Formulario 4 con fecha 26 de junio de 2025

El director John H. Noseworthy reportó la adquisición automática de 42 acciones ordinarias el 24 de junio de 2025. Las acciones representan equivalentes de dividendos sobre unidades de acciones diferidas previamente adquiridas y fueron acreditadas a un precio de transacción de $0.00. Tras este abono rutinario, la propiedad directa de Noseworthy aumenta a 6,105 acciones. No se reportaron transacciones ni disposiciones de derivados, y la presentación indica que la operación no se ejecutó bajo un plan de comercio Rule 10b5-1. El pequeño número de acciones y el costo cero indican una compra administrativa, sin impacto significativo en el flotante público o en el sentimiento de los insiders.

UnitedHealth Group Inc. (UNH) � 2025� 6� 26일자 Form 4 제출

이사 John H. Noseworthy� 2025� 6� 24일에 42� 보통�� 자동 취득� 보고했습니다. 해당 주식은 이전� 확정� 이연 주식 단위� 대� 배당� 상당액으�, 거래 가격은 $0.00� 기록되었습니�. � 일상적인 입금 � Noseworthy� 직접 소유 주식 수는 6,105�� 증가했습니다. 파생상품 거래� 처분은 보고되지 않았으며, � 거래� Rule 10b5-1 거래 계획 하에 실행되지 않았음을 제출서가 명시하고 있습니다. 적은 주식 수와 무상 취득은 행정적인 성격� 거래�, 공공 유통 주식 수나 내부� 심리� 미치� 영향� 제한적임� 시사합니�.

UnitedHealth Group Inc. (UNH) � Dépôt du Formulaire 4 daté du 26 juin 2025

Le directeur John H. Noseworthy a déclaré l'acquisition automatique de 42 actions ordinaires le 24 juin 2025. Ces actions représentent des équivalents de dividendes sur des unités d'actions différées précédemment acquises et ont été créditées à un prix de transaction de 0,00 $. Suite à ce crédit de routine, la détention directe de Noseworthy s'élève à 6 105 actions. Aucune transaction ou cession de dérivés n'a été signalée, et le dépôt indique que la transaction n'a pas été exécutée dans le cadre d'un plan de négociation Rule 10b5-1. Le faible nombre d'actions et la valeur nulle indiquent un achat administratif, sans impact significatif sur le flottant public ou le sentiment des initiés.

UnitedHealth Group Inc. (UNH) � Form 4 Einreichung vom 26. Juni 2025

Direktor John H. Noseworthy meldete den automatischen Erwerb von 42 Stammaktien am 24. Juni 2025. Die Aktien stellen Dividendenäquivalente auf zuvor erworbene, aufgeschobene Aktienanteile dar und wurden zu einem Transaktionspreis von $0,00 gutgeschrieben. Nach dieser routinemäßigen Gutschrift erhöht sich Noseworthys Direktbesitz auf 6.105 Aktien. Es wurden keine Derivatgeschäfte oder Veräußerungen gemeldet, und die Meldung weist darauf hin, dass die Transaktion nicht im Rahmen eines Rule 10b5-1 Handelsplans durchgeführt wurde. Die geringe Aktienanzahl und der Null-Kosten-Basis deuten auf einen administrativen, nicht-marktlichen Erwerb hin, der nur begrenzte Auswirkungen auf den Streubesitz oder die Insider-Stimmung hat.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine dividend-equivalent credit; immaterial to UNH valuation.

The Form 4 shows a director receiving 42 dividend-equivalent shares, a standard mechanism that keeps deferred stock units economically whole. At roughly US$480 per share (recent market price), the transaction value is under US$20k—well below materiality thresholds for a US$450 bn-cap company. There were no sales or exercise of options, so insider sentiment cannot be inferred. Overall, this is housekeeping with no bearing on forward estimates or governance risk.

TL;DR: Administrative insider accrual; governance posture unchanged.

The filing confirms compliance with Section 16 reporting timelines—filed within two business days. Because the shares stem from dividend equivalents on vested DSUs, they neither create dilution nor raise pay-for-performance concerns. The absence of a 10b5-1 plan simply reflects that the credit was automatic. No red flags or enhancements to governance quality emerge.

UnitedHealth Group Inc. (UNH) � Comunicazione Form 4 del 26 giugno 2025

Il direttore John H. Noseworthy ha riportato l'acquisizione automatica di 42 azioni ordinarie il 24 giugno 2025. Le azioni rappresentano equivalenti di dividendi su unità azionarie differite precedentemente maturate e sono state accreditate a un prezzo di transazione di $0,00. A seguito di questo accredito ordinario, la proprietà diretta di Noseworthy sale a 6.105 azioni. Non sono state segnalate operazioni o cessioni di strumenti derivati e la comunicazione indica che la transazione non è stata eseguita nell'ambito di un piano di trading Rule 10b5-1. Il numero limitato di azioni e il costo nullo indicano un acquisto di natura amministrativa, senza impatto significativo sul flottante pubblico o sul sentiment degli insider.

UnitedHealth Group Inc. (UNH) � Presentación del Formulario 4 con fecha 26 de junio de 2025

El director John H. Noseworthy reportó la adquisición automática de 42 acciones ordinarias el 24 de junio de 2025. Las acciones representan equivalentes de dividendos sobre unidades de acciones diferidas previamente adquiridas y fueron acreditadas a un precio de transacción de $0.00. Tras este abono rutinario, la propiedad directa de Noseworthy aumenta a 6,105 acciones. No se reportaron transacciones ni disposiciones de derivados, y la presentación indica que la operación no se ejecutó bajo un plan de comercio Rule 10b5-1. El pequeño número de acciones y el costo cero indican una compra administrativa, sin impacto significativo en el flotante público o en el sentimiento de los insiders.

UnitedHealth Group Inc. (UNH) � 2025� 6� 26일자 Form 4 제출

이사 John H. Noseworthy� 2025� 6� 24일에 42� 보통�� 자동 취득� 보고했습니다. 해당 주식은 이전� 확정� 이연 주식 단위� 대� 배당� 상당액으�, 거래 가격은 $0.00� 기록되었습니�. � 일상적인 입금 � Noseworthy� 직접 소유 주식 수는 6,105�� 증가했습니다. 파생상품 거래� 처분은 보고되지 않았으며, � 거래� Rule 10b5-1 거래 계획 하에 실행되지 않았음을 제출서가 명시하고 있습니다. 적은 주식 수와 무상 취득은 행정적인 성격� 거래�, 공공 유통 주식 수나 내부� 심리� 미치� 영향� 제한적임� 시사합니�.

UnitedHealth Group Inc. (UNH) � Dépôt du Formulaire 4 daté du 26 juin 2025

Le directeur John H. Noseworthy a déclaré l'acquisition automatique de 42 actions ordinaires le 24 juin 2025. Ces actions représentent des équivalents de dividendes sur des unités d'actions différées précédemment acquises et ont été créditées à un prix de transaction de 0,00 $. Suite à ce crédit de routine, la détention directe de Noseworthy s'élève à 6 105 actions. Aucune transaction ou cession de dérivés n'a été signalée, et le dépôt indique que la transaction n'a pas été exécutée dans le cadre d'un plan de négociation Rule 10b5-1. Le faible nombre d'actions et la valeur nulle indiquent un achat administratif, sans impact significatif sur le flottant public ou le sentiment des initiés.

UnitedHealth Group Inc. (UNH) � Form 4 Einreichung vom 26. Juni 2025

Direktor John H. Noseworthy meldete den automatischen Erwerb von 42 Stammaktien am 24. Juni 2025. Die Aktien stellen Dividendenäquivalente auf zuvor erworbene, aufgeschobene Aktienanteile dar und wurden zu einem Transaktionspreis von $0,00 gutgeschrieben. Nach dieser routinemäßigen Gutschrift erhöht sich Noseworthys Direktbesitz auf 6.105 Aktien. Es wurden keine Derivatgeschäfte oder Veräußerungen gemeldet, und die Meldung weist darauf hin, dass die Transaktion nicht im Rahmen eines Rule 10b5-1 Handelsplans durchgeführt wurde. Die geringe Aktienanzahl und der Null-Kosten-Basis deuten auf einen administrativen, nicht-marktlichen Erwerb hin, der nur begrenzte Auswirkungen auf den Streubesitz oder die Insider-Stimmung hat.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Noseworthy John H

(Last) (First) (Middle)
C/O UNITEDHEALTH GROUP INCORPORATED
1 HEALTH DRIVE

(Street)
EDEN PRAIRIE MN 55344

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
UNITEDHEALTH GROUP INC [ UNH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/24/2025 A 42(1) A $0 6,105 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents dividend equivalents paid on vested deferred stock units. The dividend equivalents are immediately vested and are subject to the same terms as the underlying deferred stock units.
Remarks:
Faraz A. Choudhry, Attorney-in-Fact for John H. Noseworthy M.D. 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many UnitedHealth Group (UNH) shares did Director John H. Noseworthy acquire?

42 common shares were credited on 24-Jun-2025 as dividend equivalents.

What is Director Noseworthy’s total UNH share ownership after the reported transaction?

He now directly owns 6,105 shares of UnitedHealth Group.

Was the acquisition made under a Rule 10b5-1 trading plan?

No. The filing does not check the 10b5-1 box, indicating the credit was not under a pre-arranged plan.

Did the Form 4 report any sales or derivative exercises?

No. Only an acquisition of dividend-equivalent stock was disclosed; no sales or derivatives were involved.

When was the Form 4 for UNH filed with the SEC?

The document was filed on 26-Jun-2025, two days after the transaction date.
Unitedhealth Gp

NYSE:UNH

UNH Rankings

UNH Latest News

UNH Latest SEC Filings

UNH Stock Data

246.17B
904.48M
0.27%
90.58%
1.4%
Healthcare Plans
Hospital & Medical Service Plans
United States
EDEN PRAIRIE